Literature DB >> 12244138

Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity.

Andrew G Cawthon1, Martha A Alexander-Miller.   

Abstract

The improved efficacy of high avidity CTL for clearance of virus has been well-documented. Thus, elucidation of the mechanisms that confer the increased sensitivity to peptide ligand demonstrated by high avidity CTL is critical. Using CTL lines of high and low avidity generated from a TCR transgenic mouse, we have found that functional avidity can be controlled by the expression of CD8alphaalpha vs CD8alphabeta and the ability of CTLs to colocalize the TCR and CD8 in the membrane. Colocalization of these molecules was mediated by lipid rafts and importantly, raft disruption resulted in the conversion of high avidity CTL into a lower functional avidity phenotype. These novel findings provide insights into the control of functional avidity in response to viral infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244138     DOI: 10.4049/jimmunol.169.7.3492

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement.

Authors:  Samantha E Kerry; Jennifer Buslepp; Lorraine A Cramer; Robert Maile; Lucinda L Hensley; Alma I Nielsen; Paula Kavathas; Barbara J Vilen; Edward J Collins; Jeffrey A Frelinger
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

2.  IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

Authors:  SangKon Oh; Liyanage P Perera; Donald S Burke; Thomas A Waldmann; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

3.  Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.

Authors:  Michael S Bennett; Aviva Joseph; Hwee L Ng; Harris Goldstein; Otto O Yang
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

Review 4.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 5.  High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors.

Authors:  Martha A Alexander-Miller
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity.

Authors:  Jasper G van den Boorn; I Caroline Le Poole; Rosalie M Luiten
Journal:  Int Rev Immunol       Date:  2006 May-Aug       Impact factor: 5.311

Review 7.  Class II major histocompatibility complex tetramer staining: progress, problems, and prospects.

Authors:  Sabrina S Vollers; Lawrence J Stern
Journal:  Immunology       Date:  2008-03       Impact factor: 7.397

8.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

9.  In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection.

Authors:  Beth C Holbrook; Rama D Yammani; Lance K Blevins; Martha A Alexander-Miller
Journal:  Viral Immunol       Date:  2013-08-24       Impact factor: 2.257

10.  Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity.

Authors:  Logan K Smith; Giselle M Boukhaled; Stephanie A Condotta; Sabrina Mazouz; Jenna J Guthmiller; Rahul Vijay; Noah S Butler; Julie Bruneau; Naglaa H Shoukry; Connie M Krawczyk; Martin J Richer
Journal:  Immunity       Date:  2018-01-23       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.